Professor Robert Jones

  • Professor of Clinical Cancer Research (Clinical Trials Research)

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • TASTER (TArgeting STEm cell Resistance) - Defining leukaemic cell clonal architecture to inform and monitor drug responses in the TASTER CML Phase II Clinical Trial
    Cancer Research UK
    2018 - 2019
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2018
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • Precision-Panc: a dynamic therapeutic development platform for pancreatic cancer
    Cancer Research UK
    2017 - 2019
     
  • Real-world experience of Radum-223 in metastatic castration resistant prostate cancer, a UK study
    Bayer plc
    2017 - 2019
     
  • Real-world experience of Radum-223 in metastatic castration resistant prostate cancer, a UK study
    NHS Greater Glasgow and Clyde
    2017 - 2020
     
  • PARADIGM-2: Olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in newly diagnosed glioblastoma stratified by MGMT status: 2 parallel phase I studies
    Cancer Research UK
    2016 - 2020
     
  • ATLANTIS - Maintaining response in Urothelial Cancer: A Personalised Medicine Trial
    Cancer Research UK
    2016 - 2017
     
  • A clinical research fellowship in cancer clinical trials
    Cancer Research UK
    2015 - 2017
     
  • Combined Suppression of cholesterol bioavailability and androgen de novo syntheseis to treat castrate resistant prostate cancer
    Prostate Cancer UK
    2015 - 2019
     
  • Evaluating cancer services across the NHS in Scotland, Wales and Northern Ireland.
    Cancer Research UK
    2015 - 2016
     
  • Optimising the use of chemotherapy in prostate cancer
    Prostate Cancer Research Foundation
    2015 - 2018
     
  • Investment to support purchase of electronic remote data capture (eRDC) system for clinical trials
    Cancer Research UK
    2015 - 2017
     
  • Cancer Research UK Clinical Trials Unit - Core Programme Funding
    Cancer Research UK
    2013 - 2018
     
  • The effect of Dasatinib administration on metastases gene expression in early and late stage prostate cancer in vitro
    Cancer Research UK
    2012 - 2013
     
  • MAdCaP: Mdm2 inhibition and Abiraterone in Carcinoma of the Prostate - a randomized phase II trial of abiraterone acetate with or without RO5045337
    Cancer Research UK
    2012 - 2016
     
  • CROP Imaging substudy to the main trial (A randomised controlled trial of deferred androgen deprivation therapy +/- upfront cryotherapy in men with localised radiation recurrent prostate cancer.
    Cancer Research UK
    2012 - 2013
     
  • A randomised controlled trial of deferred androgen deprivation therapy +/- upfront cryotherapy in men with localised radiation recurrent prostate cancer (RRPC) to evaluate efficacy and tolerability
    Cancer Research UK
    2011 - 2013
     
  • Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC): proteomic reconstruction of molecular pathways to predict renal cell cancer recurrence and response to treatment
    Chief Scientist Office
    2010 - 2013
     
  • Biomarkers of Invasion: Methodology, feasibility and pre-clinical modelling
    NHS Greater Glasgow and Clyde Endowment Funds
    2007 - 2010
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2003 | 2002 | 2001
Number of items: 80.

2018

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi:10.1136/heartjnl-2018-313726) (PMID:30228246)

Paterson, C. et al. (2018) Radiotherapy induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease oral spray versus placebo in head and neck cancer patients. British Journal of Oral and Maxillofacial Surgery, (Accepted for Publication)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi:10.1093/annonc/mdy072) (PMID:29529169)

Schmidinger, M., Danesi, R., Jones, R. , McDermott, R., Pyle, L., Rini, B. and Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14(9), pp. 861-875. (doi:10.2217/fon-2017-0455) (PMID:29264944)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi:10.1111/bju.14025) (PMID:28940952)

Bilsland, A., Kelly, C., Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi:10.1038/s41416-018-0299-z)

2017

Ross, K. and Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131(21), pp. 2627-2642. (doi:10.1042/CS20160894) (PMID:29079639)

MacLennan, S. et al. (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International, 120(5B), E64-E79. (doi:10.1111/bju.13854) (PMID:28346770)

Escudier, B. et al. (2017) A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Targeted Oncology, 12(5), pp. 655-661. (doi:10.1007/s11523-017-0525-2) (PMID:28798986)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi:10.1056/NEJMoa1702900) (PMID:28578639)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi:10.1200/JCO.2016.70.7828) (PMID:28402747)

Gore, M. E., Jones, R. J. , Ravaud, A., Kuczyk, M., Demkow, T., Bearz, A., Shapiro, J., Strauss, U. P. and Porta, C. (2017) Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU International, 119(6), pp. 846-853. (doi:10.1111/bju.13740) (PMID:27981711)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi:10.1200/JCO.2016.69.0677) (PMID:28300506)

Jones, R. J. and Brown, J. (2017) Circulating biomarkers in cancer care: what possible use? Practical Laboratory Medicine, 7, pp. 45-48. (doi:10.1016/j.plabm.2016.04.004) (PMID:28856218) (PMCID:PMC5575409)

Powles, T. et al. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. Journal of Clinical Oncology, 35(1), pp. 48-55. (doi:10.1200/JCO.2015.66.3468) (PMID:28034079)

2016

Conteduca, V. et al. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20(3), pp. 255-263. (doi:10.1007/s40291-016-0196-1) (PMID:27020582)

Davda, R., Hughes, S., Jones, R. , Crabb, S.J., Troup, J. and Payne, H. (2016) Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer. Clinical Oncology, 28(6), pp. 376-385. (doi:10.1016/j.clon.2016.01.006) (PMID:26874654)

Armstrong, A. J. et al. (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, 17(3), pp. 378-388. (doi:10.1016/S1470-2045(15)00515-X) (PMID:26794930)

Conteduca, V. et al. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11(7), e0158952. (doi:10.1371/journal.pone.0158952) (PMID:27434372) (PMCID:PMC4951050)

James, N. D. et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform-randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. (doi:10.1016/S0140-6736(15)01037-5) (PMID:26719232)

Powles, T. et al. (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27(5), pp. 880-886. (doi:10.1093/annonc/mdw014) (PMID:26802156)

Roseweir, A. K. , Qayyum, T., Lim, Z., Hammond, R., MacDonald, A. I., Fraser, S., Oades, G. M., Aitchison, M., Jones, R. J. and Edwards, J. (2016) Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 16, p. 229. (doi:10.1186/s12885-016-2254-9) (PMID:26984511) (PMCID:PMC4794832)

2015

Bahl, A. et al. (2015) Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU International, 116(6), pp. 880-887. (doi:10.1111/bju.13069) (PMID:25639506)

Hanna, C. and Jones, R. J. (2015) Emerging treatments for recurrent prostate cancer. Future Oncology, 11(21), pp. 2873-2880. (doi:10.2217/fon.15.228) (PMID:26436556)

Eisen, T., Loembé, A.-B., Shparyk, Y., MacLeod, N., Jones, R.J. , Mazurkiewicz, M., Temple, G., Dressler, H. and Bondarenko, I. (2015) A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 113(8), pp. 1140-1147. (doi:10.1038/bjc.2015.313) (PMID:26448178) (PMCID:PMC4647871)

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi:10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Mateo, J. et al. (2015) DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine, 373(18), pp. 1697-1708. (doi:10.1056/NEJMoa1506859) (PMID:26510020)

Huddart, R.A., Jones, R. and Choudhury, A. (2015) A new dawn for bladder cancer? Recommendations from the national institute for health and care excellence (NICE) on managing bladder cancer. Clinical Oncology, 27(7), pp. 380-381. (doi:10.1016/j.clon.2015.03.008) (PMID:25869257)

James, N. D. et al. (2015) Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 67(6), pp. 1028-1038. (doi:10.1016/j.eururo.2014.09.032) (PMID:25301760)

Omlin, A. et al. (2015) AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 33(3), pp. 679-690. (doi:10.1007/s10637-015-0235-5) (PMID:25920479)

Geldart, T. et al. (2015) SUCCINCT: an open-label, single-arm, non-randomised, Phase 2 Trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology, 67(4), pp. 599-602. (doi:10.1016/j.eururo.2014.11.003)

Fizazi, K. et al. (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of Clinical Oncology, 33(7), pp. 723-731. (doi:10.1200/JCO.2014.56.5119) (PMID:25624429)

Saad, F. et al. (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncology, 16(3), pp. 338-348. (doi:10.1016/S1470-2045(15)70027-6) (PMID:25701170)

Jones, R. J. (2015) Making trials work in practice: please mind the gap. European Urology, 67(2), pp. 250-251. (doi:10.1016/j.eururo.2014.10.006)

Harris, R., Oake, K., Hawkins, R. E., Jones, R. J. , Powles, T. and Montgomery, D. A. (2015) Patient needs in advanced renal cell carcinoma: what are patients’ priorities and how well are we meeting them. Patient Experience Journal, 2(2), 18.

Payne, H., Davda, R., Jones, R. , Crabb, S., Troup, J. and Hughes, S. (2015) Advances in advanced prostate cancer - the continuing journey. BJU International, 118(1), pp. 17-19. (doi:10.1111/bju.13350) (PMID:26456636)

2014

Muinonen-Martin, A. J. et al. (2014) Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLoS Biology, 12(10), e1001966. (PMID:25313567) (PMCID:PMC4196730)

Loriot, Y. et al. (2014) Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs, 32(5), pp. 995-1004. (doi:10.1007/s10637-014-0101-x)

Jones, R. J. (2014) Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence. European Urology, 66(3), pp. 466-467. (doi:10.1016/j.eururo.2013.12.053)

Powles, T. et al. (2014) A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. European Journal of Cancer, 50(12), pp. 2057-64. (doi:10.1016/j.ejca.2014.04.021)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi:10.1002/bjs.9510)

Molife, L. .R. et al. (2014) Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology, 10(2), pp. 219-231. (doi:10.2217/fon.13.250)

Michaelson, M. D. et al. (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology, 32(2), pp. 76-82. (doi:10.1200/JCO.2012.48.5268)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi:10.1038/bjc.2014.316)

2013

Eisen, T. et al. (2013) Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs, 31(5), pp. 1283-1293. (doi:10.1007/s10637-013-9962-7)

Jones, R. and DeSantis, M. (2013) Access to targeted therapies in renal cell cancer. Seminars in Oncology, 40(4), pp. 521-528. (doi:10.1053/j.seminoncol.2013.05.012)

Ford, J. et al. (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 17(29), pp. 1-386. (doi:10.3310/hta17290)

Jones, R. (2013) Urological medical oncology: land of opportunity. Future Oncology, 9(2), pp. 149-152. (doi:10.2217/FON.12.176)

Ford, J.A., Jones, R. , Elders, A., Mulatero, C., Royle, P., Sharma, P., Stewart, F., Todd, R. and Mowatt, G. (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. European Journal of Cancer, 49(2), pp. 416-430. (doi:10.1016/j.ejca.2012.07.016)

Jones, R. et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs, 31(4), pp. 1001-1007. (doi:10.1007/s10637-013-9926-y)

Motzer, R.J. et al. (2013) Pazopanib versus Sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369(8), pp. 722-731. (doi:10.1056/NEJMoa1303989)

Salazar, R. et al. (2013) A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 70(5), pp. 673-681. (doi:10.1007/s00280-012-1951-6)

Venugopal, B., Ansari, J., Aitchison, M., Tho, L., Campbell, R. and Jones, R.J. (2013) Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology, 13(26), (doi:10.1186/1471-2490-13-26)

2012

Logothetis, C.J. et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, 13(12), pp. 1210-1217. (doi:10.1016/S1470-2045(12)70473-4)

Olmos, D. et al. (2012) Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, 13(11), pp. 1114-1124. (doi:10.1016/S1470-2045(12)70372-8)

Powles, T. et al. (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European Journal of Cancer, 48(17), pp. 3171-3176. (doi:10.1016/j.ejca.2012.05.022)

Fizazi, K. et al. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13(10), pp. 983-992. (doi:10.1016/S1470-2045(12)70379-0)

Ford, J.A., Mowatt, G. and Jones, R.J. (2012) Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Review of Clinical Pharmacology, 5(3), pp. 271-279. (doi:10.1586/ecp.12.21)

Kaye, S. et al. (2012) Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer, 106(11), pp. 1728-1734. (doi:10.1038/bjc.2012.158)

Leach, M.O. et al. (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology, 22(7), pp. 1451-1464. (doi:10.1007/s00330-012-2446-x)

Qayyum, T. et al. (2012) Abstracts of the 10th International Kidney Cancer Symposium: The role of Src kinase in renal cell cancer. BJU International, 109(S5), p. 10. (doi:10.1111/j.1464-410X.2012.11171.x)

Qayyum, T. et al. (2012) Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 107(5), pp. 856-863. (doi:10.1038/bjc.2012.314)

2011

Harrington, J.A. and Jones, R.J. (2011) Management of metastatic castration-resistant prostate cancer after first-line docetaxel. European Journal of Cancer, 47(14), pp. 2133-2142. (doi:10.1016/j.ejca.2011.04.036)

de Bono, J.S. et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), pp. 1995-2005. (doi:10.1056/NEJMoa1014618)

Le Pechoux, C. et al. (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), pp. 1154-1163. (doi:10.1093/annonc/mdq576)

Powles, T., Chowdhury, S., Jones, R. , Mantle, M., Nathan, P., Bex, A., Lim, L. and Hutson, T. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 104(5), pp. 741-745. (doi:10.1038/sj.bjc.6606061)

Jones, R.J. , Green, T.P. and Elvin, P. (2011) Discovery and development of drugs targeting tumour invasion and metastasis. In: Lyden, D., Welch, D.R. and Psaila, B. (eds.) Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press, pp. 600-611. ISBN 9780521887212

2010

Powles, T., Jones, R.J. , Chowdhury, S., Shamash, J., Mantle, M., Lim, L. and Hutson, T. (2010) The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? BJU International, 106(4), pp. 453-457. (doi:10.1111/j.1464-410X.2010.09466.x)

2009

Paterson, C. and Jones, R.J. (2009) Tumour Flare during Interruption of Temsirolimus Treatment for Metastatic Renal Cell Cancer. Clinical Oncology, 21(9), pp. 732-733. (doi:10.1016/j.clon.2009.07.006)

Jones, R. J. et al. (2009) Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment, 114(2), pp. 211-221. (doi:10.1007/s10549-008-9997-1)

2008

Jones, R. , Hawkins, R., Eatock, M., Ferry, D., Eskens, F., Wilke, H. and Evans, T. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61(3), pp. 435-441. (doi:10.1007/s00280-007-0486-8)

Twelves, C., Trigo, J. M., Jones, R. , De Rosa, F., Rakhit, A., Fettner, S., Wright, T. and Baselga, J. (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. European Journal of Cancer, 44(3), pp. 419-426. (doi:10.1016/j.ejca.2007.12.011)

Jones, R.J. , Boyce, T., Fennell, M., Jacobs, V., Pinto, F., Duffield, E., Clack, G., Green, T., Kelly, J. and Robertson, J. (2008) The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemotherapy and Pharmacology, 61(1), pp. 23-32. (doi:10.1007/s00280-007-0440-9)

2007

Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R. , Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A. and Diaz-Rubio, E. (2007) Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clinical Cancer Research, 13(2), pp. 523-531. (doi:10.1158/1078-0432.CCR-06-1627)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

2003

Glen, H. and Jones, R.J. (2003) 8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003. Breast Cancer Research, 5(4), pp. 198-201. (doi:10.1186/bcr611)

2002

Jones, R. , Avizienyte, E., Wyke, A., Owens, D., Brunton, V. and Frame, M. (2002) Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM1 2C human colorectal cancer cells. British Journal of Cancer, 87(10), pp. 1128-1135. (doi:10.1038/sj.bjc.6600594)

Avizienyte, E., Wyke, A., Jones, R. , McLean, G., Westhoff, M., Brunton, V. and Frame, M. (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nature Cell Biology, 4(8), pp. 632-638. (doi:10.1038/ncb829)

Jones, R. and Twelves, C. (2002) Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Expert Review of Anticancer Therapy, 2(1), pp. 13-22. (doi:10.1586/14737140.2.1.13)

2001

Twelves, C. and Jones, R. (2001) Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy, 2(9), pp. 1495-1505. (doi:10.1517/14656566.2.9.1495)

This list was generated on Sun Dec 16 08:41:55 2018 GMT.
Number of items: 80.

Articles

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi:10.1136/heartjnl-2018-313726) (PMID:30228246)

Paterson, C. et al. (2018) Radiotherapy induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease oral spray versus placebo in head and neck cancer patients. British Journal of Oral and Maxillofacial Surgery, (Accepted for Publication)

Sydes, M. R. et al. (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 29(5), pp. 1235-1248. (doi:10.1093/annonc/mdy072) (PMID:29529169)

Schmidinger, M., Danesi, R., Jones, R. , McDermott, R., Pyle, L., Rini, B. and Négrier, S. (2018) Individualized dosing with axitinib: rationale and practical guidance. Future Oncology, 14(9), pp. 861-875. (doi:10.2217/fon-2017-0455) (PMID:29264944)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi:10.1111/bju.14025) (PMID:28940952)

Ross, K. and Jones, R. J. (2017) Immune checkpoint inhibitors in renal cell carcinoma. Clinical Science, 131(21), pp. 2627-2642. (doi:10.1042/CS20160894) (PMID:29079639)

MacLennan, S. et al. (2017) A core outcome set for localised prostate cancer effectiveness trials. BJU International, 120(5B), E64-E79. (doi:10.1111/bju.13854) (PMID:28346770)

Escudier, B. et al. (2017) A phase II multicentre, open-label, proof-of-concept study of tasquinimod in hepatocellular, ovarian, renal cell, and gastric cancers. Targeted Oncology, 12(5), pp. 655-661. (doi:10.1007/s11523-017-0525-2) (PMID:28798986)

James, N. D. et al. (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine, 377(4), pp. 338-351. (doi:10.1056/NEJMoa1702900) (PMID:28578639)

Jones, R. J. et al. (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. Journal of Clinical Oncology, 35(16), pp. 1770-1777. (doi:10.1200/JCO.2016.70.7828) (PMID:28402747)

Gore, M. E., Jones, R. J. , Ravaud, A., Kuczyk, M., Demkow, T., Bearz, A., Shapiro, J., Strauss, U. P. and Porta, C. (2017) Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. BJU International, 119(6), pp. 846-853. (doi:10.1111/bju.13740) (PMID:27981711)

Mason, M. D. et al. (2017) Adding celecoxib with or without zoledronic acid for hormone-naïve prostate cancer: long-term survival results from an adaptive, multiarm, multistage, platform, randomized controlled trial. Journal of Clinical Oncology, 35(14), pp. 1530-1541. (doi:10.1200/JCO.2016.69.0677) (PMID:28300506)

Jones, R. J. and Brown, J. (2017) Circulating biomarkers in cancer care: what possible use? Practical Laboratory Medicine, 7, pp. 45-48. (doi:10.1016/j.plabm.2016.04.004) (PMID:28856218) (PMCID:PMC5575409)

Powles, T. et al. (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. Journal of Clinical Oncology, 35(1), pp. 48-55. (doi:10.1200/JCO.2015.66.3468) (PMID:28034079)

Conteduca, V. et al. (2016) Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer. Molecular Diagnosis and Therapy, 20(3), pp. 255-263. (doi:10.1007/s40291-016-0196-1) (PMID:27020582)

Davda, R., Hughes, S., Jones, R. , Crabb, S.J., Troup, J. and Payne, H. (2016) Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer. Clinical Oncology, 28(6), pp. 376-385. (doi:10.1016/j.clon.2016.01.006) (PMID:26874654)

Armstrong, A. J. et al. (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncology, 17(3), pp. 378-388. (doi:10.1016/S1470-2045(15)00515-X) (PMID:26794930)

Conteduca, V. et al. (2016) Persistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS ONE, 11(7), e0158952. (doi:10.1371/journal.pone.0158952) (PMID:27434372) (PMCID:PMC4951050)

James, N. D. et al. (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform-randomised controlled trial. Lancet, 387(10024), pp. 1163-1177. (doi:10.1016/S0140-6736(15)01037-5) (PMID:26719232)

Powles, T. et al. (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27(5), pp. 880-886. (doi:10.1093/annonc/mdw014) (PMID:26802156)

Roseweir, A. K. , Qayyum, T., Lim, Z., Hammond, R., MacDonald, A. I., Fraser, S., Oades, G. M., Aitchison, M., Jones, R. J. and Edwards, J. (2016) Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer, 16, p. 229. (doi:10.1186/s12885-016-2254-9) (PMID:26984511) (PMCID:PMC4794832)

Bahl, A. et al. (2015) Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU International, 116(6), pp. 880-887. (doi:10.1111/bju.13069) (PMID:25639506)

Hanna, C. and Jones, R. J. (2015) Emerging treatments for recurrent prostate cancer. Future Oncology, 11(21), pp. 2873-2880. (doi:10.2217/fon.15.228) (PMID:26436556)

Eisen, T., Loembé, A.-B., Shparyk, Y., MacLeod, N., Jones, R.J. , Mazurkiewicz, M., Temple, G., Dressler, H. and Bondarenko, I. (2015) A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 113(8), pp. 1140-1147. (doi:10.1038/bjc.2015.313) (PMID:26448178) (PMCID:PMC4647871)

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi:10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Mateo, J. et al. (2015) DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine, 373(18), pp. 1697-1708. (doi:10.1056/NEJMoa1506859) (PMID:26510020)

Huddart, R.A., Jones, R. and Choudhury, A. (2015) A new dawn for bladder cancer? Recommendations from the national institute for health and care excellence (NICE) on managing bladder cancer. Clinical Oncology, 27(7), pp. 380-381. (doi:10.1016/j.clon.2015.03.008) (PMID:25869257)

James, N. D. et al. (2015) Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology, 67(6), pp. 1028-1038. (doi:10.1016/j.eururo.2014.09.032) (PMID:25301760)

Omlin, A. et al. (2015) AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Investigational New Drugs, 33(3), pp. 679-690. (doi:10.1007/s10637-015-0235-5) (PMID:25920479)

Geldart, T. et al. (2015) SUCCINCT: an open-label, single-arm, non-randomised, Phase 2 Trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. European Urology, 67(4), pp. 599-602. (doi:10.1016/j.eururo.2014.11.003)

Fizazi, K. et al. (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Journal of Clinical Oncology, 33(7), pp. 723-731. (doi:10.1200/JCO.2014.56.5119) (PMID:25624429)

Saad, F. et al. (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncology, 16(3), pp. 338-348. (doi:10.1016/S1470-2045(15)70027-6) (PMID:25701170)

Jones, R. J. (2015) Making trials work in practice: please mind the gap. European Urology, 67(2), pp. 250-251. (doi:10.1016/j.eururo.2014.10.006)

Harris, R., Oake, K., Hawkins, R. E., Jones, R. J. , Powles, T. and Montgomery, D. A. (2015) Patient needs in advanced renal cell carcinoma: what are patients’ priorities and how well are we meeting them. Patient Experience Journal, 2(2), 18.

Payne, H., Davda, R., Jones, R. , Crabb, S., Troup, J. and Hughes, S. (2015) Advances in advanced prostate cancer - the continuing journey. BJU International, 118(1), pp. 17-19. (doi:10.1111/bju.13350) (PMID:26456636)

Muinonen-Martin, A. J. et al. (2014) Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. PLoS Biology, 12(10), e1001966. (PMID:25313567) (PMCID:PMC4196730)

Loriot, Y. et al. (2014) Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Investigational New Drugs, 32(5), pp. 995-1004. (doi:10.1007/s10637-014-0101-x)

Jones, R. J. (2014) Sequencing systemic therapies in advanced prostate cancer: spoiled for choice but not for evidence. European Urology, 66(3), pp. 466-467. (doi:10.1016/j.eururo.2013.12.053)

Powles, T. et al. (2014) A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. European Journal of Cancer, 50(12), pp. 2057-64. (doi:10.1016/j.ejca.2014.04.021)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi:10.1002/bjs.9510)

Molife, L. .R. et al. (2014) Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncology, 10(2), pp. 219-231. (doi:10.2217/fon.13.250)

Michaelson, M. D. et al. (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology, 32(2), pp. 76-82. (doi:10.1200/JCO.2012.48.5268)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi:10.1038/bjc.2014.316)

Eisen, T. et al. (2013) Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs, 31(5), pp. 1283-1293. (doi:10.1007/s10637-013-9962-7)

Jones, R. and DeSantis, M. (2013) Access to targeted therapies in renal cell cancer. Seminars in Oncology, 40(4), pp. 521-528. (doi:10.1053/j.seminoncol.2013.05.012)

Ford, J. et al. (2013) Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 17(29), pp. 1-386. (doi:10.3310/hta17290)

Jones, R. (2013) Urological medical oncology: land of opportunity. Future Oncology, 9(2), pp. 149-152. (doi:10.2217/FON.12.176)

Ford, J.A., Jones, R. , Elders, A., Mulatero, C., Royle, P., Sharma, P., Stewart, F., Todd, R. and Mowatt, G. (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. European Journal of Cancer, 49(2), pp. 416-430. (doi:10.1016/j.ejca.2012.07.016)

Jones, R. et al. (2013) Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs, 31(4), pp. 1001-1007. (doi:10.1007/s10637-013-9926-y)

Motzer, R.J. et al. (2013) Pazopanib versus Sunitinib in metastatic renal-cell carcinoma. New England Journal of Medicine, 369(8), pp. 722-731. (doi:10.1056/NEJMoa1303989)

Salazar, R. et al. (2013) A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 70(5), pp. 673-681. (doi:10.1007/s00280-012-1951-6)

Venugopal, B., Ansari, J., Aitchison, M., Tho, L., Campbell, R. and Jones, R.J. (2013) Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology, 13(26), (doi:10.1186/1471-2490-13-26)

Logothetis, C.J. et al. (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncology, 13(12), pp. 1210-1217. (doi:10.1016/S1470-2045(12)70473-4)

Olmos, D. et al. (2012) Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncology, 13(11), pp. 1114-1124. (doi:10.1016/S1470-2045(12)70372-8)

Powles, T. et al. (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European Journal of Cancer, 48(17), pp. 3171-3176. (doi:10.1016/j.ejca.2012.05.022)

Fizazi, K. et al. (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology, 13(10), pp. 983-992. (doi:10.1016/S1470-2045(12)70379-0)

Ford, J.A., Mowatt, G. and Jones, R.J. (2012) Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes. Expert Review of Clinical Pharmacology, 5(3), pp. 271-279. (doi:10.1586/ecp.12.21)

Kaye, S. et al. (2012) Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer, 106(11), pp. 1728-1734. (doi:10.1038/bjc.2012.158)

Leach, M.O. et al. (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology, 22(7), pp. 1451-1464. (doi:10.1007/s00330-012-2446-x)

Qayyum, T. et al. (2012) Abstracts of the 10th International Kidney Cancer Symposium: The role of Src kinase in renal cell cancer. BJU International, 109(S5), p. 10. (doi:10.1111/j.1464-410X.2012.11171.x)

Qayyum, T. et al. (2012) Expression and prognostic significance of Src family members in renal clear cell carcinoma. British Journal of Cancer, 107(5), pp. 856-863. (doi:10.1038/bjc.2012.314)

Harrington, J.A. and Jones, R.J. (2011) Management of metastatic castration-resistant prostate cancer after first-line docetaxel. European Journal of Cancer, 47(14), pp. 2133-2142. (doi:10.1016/j.ejca.2011.04.036)

de Bono, J.S. et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), pp. 1995-2005. (doi:10.1056/NEJMoa1014618)

Le Pechoux, C. et al. (2011) Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), pp. 1154-1163. (doi:10.1093/annonc/mdq576)

Powles, T., Chowdhury, S., Jones, R. , Mantle, M., Nathan, P., Bex, A., Lim, L. and Hutson, T. (2011) Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 104(5), pp. 741-745. (doi:10.1038/sj.bjc.6606061)

Powles, T., Jones, R.J. , Chowdhury, S., Shamash, J., Mantle, M., Lim, L. and Hutson, T. (2010) The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? BJU International, 106(4), pp. 453-457. (doi:10.1111/j.1464-410X.2010.09466.x)

Paterson, C. and Jones, R.J. (2009) Tumour Flare during Interruption of Temsirolimus Treatment for Metastatic Renal Cell Cancer. Clinical Oncology, 21(9), pp. 732-733. (doi:10.1016/j.clon.2009.07.006)

Jones, R. J. et al. (2009) Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment, 114(2), pp. 211-221. (doi:10.1007/s10549-008-9997-1)

Jones, R. , Hawkins, R., Eatock, M., Ferry, D., Eskens, F., Wilke, H. and Evans, T. (2008) A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 61(3), pp. 435-441. (doi:10.1007/s00280-007-0486-8)

Twelves, C., Trigo, J. M., Jones, R. , De Rosa, F., Rakhit, A., Fettner, S., Wright, T. and Baselga, J. (2008) Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. European Journal of Cancer, 44(3), pp. 419-426. (doi:10.1016/j.ejca.2007.12.011)

Jones, R.J. , Boyce, T., Fennell, M., Jacobs, V., Pinto, F., Duffield, E., Clack, G., Green, T., Kelly, J. and Robertson, J. (2008) The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. Cancer Chemotherapy and Pharmacology, 61(1), pp. 23-32. (doi:10.1007/s00280-007-0440-9)

Hanauske, A., Cassidy, J., Sastre, J., Bolling, C., Jones, R. , Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A. and Diaz-Rubio, E. (2007) Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clinical Cancer Research, 13(2), pp. 523-531. (doi:10.1158/1078-0432.CCR-06-1627)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

Glen, H. and Jones, R.J. (2003) 8th international conference: primary therapy of early breast cancer, St Gallen, Switzerland, March 12-15 2003. Breast Cancer Research, 5(4), pp. 198-201. (doi:10.1186/bcr611)

Jones, R. , Avizienyte, E., Wyke, A., Owens, D., Brunton, V. and Frame, M. (2002) Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM1 2C human colorectal cancer cells. British Journal of Cancer, 87(10), pp. 1128-1135. (doi:10.1038/sj.bjc.6600594)

Avizienyte, E., Wyke, A., Jones, R. , McLean, G., Westhoff, M., Brunton, V. and Frame, M. (2002) Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nature Cell Biology, 4(8), pp. 632-638. (doi:10.1038/ncb829)

Jones, R. and Twelves, C. (2002) Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514). Expert Review of Anticancer Therapy, 2(1), pp. 13-22. (doi:10.1586/14737140.2.1.13)

Twelves, C. and Jones, R. (2001) Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy, 2(9), pp. 1495-1505. (doi:10.1517/14656566.2.9.1495)

Book Sections

Jones, R.J. , Green, T.P. and Elvin, P. (2011) Discovery and development of drugs targeting tumour invasion and metastasis. In: Lyden, D., Welch, D.R. and Psaila, B. (eds.) Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press, pp. 600-611. ISBN 9780521887212

Conference or Workshop Item

Bilsland, A., Kelly, C., Roccisana, J., Paul, J. , Jones, R. , Edwards, J. , Roseweir, A. , Stein, T. and West, K. (2018) An Exploratory Study on the Use of Game-based Learning Using Microsoft Kinect to Teach Oncology Phase I Clinical Trial Designs. 2018 NCRI Cancer Conference, Glasgow, UK, 04-06 Nov 2018. (doi:10.1038/s41416-018-0299-z)

This list was generated on Sun Dec 16 08:41:55 2018 GMT.